Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | RET | P07949 | 1/20 | 0.32 |
| ▸ | PI4KA | P42356 | 1/20 | 0.32 |
| ▸ | XDH | P47989 | 1/20 | 0.32 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.32 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.32 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.32 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29402652 | 1.00 | KDM4E (0.34) | KDM4EALDH1A1LMNAGAAL3MBTL1 | |
| SCHEMBL29607726 | 0.79 | PDPK1 (0.32) | RETPI4KAXDHLRRK2PI4K2B | |
| SCHEMBL17825577 | 0.76 | AOC1 (0.41) | — | |
| SCHEMBL1321549 | 0.74 | RET (0.52) | KDM4EGAARETPI4KAXDH | |
| SCHEMBL31001140 | 0.74 | RET (0.52) | KDM4EGAARETPI4KAXDH | |
| SCHEMBL3986884 | 0.72 | RET (0.36) | LMNARETPI4KAXDHLRRK2 | |
| SCHEMBL29993245 | 0.72 | XDH (0.55) | ALDH1A1LMNARETPI4KAXDH | |
| SCHEMBL19250873 | 0.71 | MAPK1 (0.34) | LRRK2MAPK1 | |
| SCHEMBL5705726 | 0.71 | RET (0.35) | RETPI4KAXDHLRRK2PI4K2B | |
| SCHEMBL5246712 | 0.71 | RET (0.35) | RETPI4KAXDHLRRK2PI4K2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3894413-B1 | PYRAZOLOPYRIMIDINE PDE9 INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2023-11-15 | — | — | EP | claimed |
| EP-3894413-A1 | PYRAZOLOPYRIMIDINE PDE9 INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2021-10-20 | — | — | EP | claimed |
| EP-3893881-A1 | CYCLOBUTYL PYRAZOLOPYRIMIDINE PDE9 INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2021-10-20 | — | — | EP | claimed |
| WO-2020123272-A1 | PYRAZOLOPYRIMIDINE PDE9 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2020-06-18 | — | — | WO | claimed |
| WO-2020123271-A1 | CYCLOBUTYL PYRAZOLOPYRIMIDINE PDE9 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2020-06-18 | — | — | WO | claimed |
| EP-3634964-A1 | PYRAZOLOPYRIMIDINE PDE9 INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2020-04-15 | — | — | EP | claimed |
| WO-2018226771-A1 | PYRAZOLOPYRIMIDINE PDE9 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2018-12-13 | — | — | WO | claimed |
| US-20250360137-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | FREEDOM BIOSCIENCES INC (US) | 2025-11-27 | — | — | US | disclosed |
| WO-2024107445-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | FREEDOM BIOSCIENCES, INC. (US) | 2024-05-23 | — | — | WO | disclosed |
| EP-3894413-B1 | PYRAZOLOPYRIMIDINE PDE9 INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2023-11-15 | — | — | EP | disclosed |
| EP-3634964-B1 | PYRAZOLOPYRIMIDINE PDE9 INHIBITORS | MERCK SHARP & DOHME (US) | 2022-02-23 | — | — | EP | disclosed |
| EP-3893881-A1 | CYCLOBUTYL PYRAZOLOPYRIMIDINE PDE9 INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2021-10-20 | — | — | EP | disclosed |
| EP-3894413-A1 | PYRAZOLOPYRIMIDINE PDE9 INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2021-10-20 | — | — | EP | disclosed |
| WO-2020123272-A1 | PYRAZOLOPYRIMIDINE PDE9 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2020-06-18 | — | — | WO | disclosed |
| WO-2020123271-A1 | CYCLOBUTYL PYRAZOLOPYRIMIDINE PDE9 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2020-06-18 | — | — | WO | disclosed |
| EP-3634964-A1 | PYRAZOLOPYRIMIDINE PDE9 INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2020-04-15 | — | — | EP | disclosed |
| WO-2018226771-A1 | PYRAZOLOPYRIMIDINE PDE9 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2018-12-13 | — | — | WO | disclosed |
| EP-2132207-A2 | HETEROCYCLIC COMPOUNDS AND THEIR USES | Amgen Inc. (US) | 2009-12-16 | — | — | EP | disclosed |
| WO-2008118454-A2 | DERIVATIVES OF QUINOLINE OR BENZOPYRAZINE AND THEIR USES FOR THE TREATMENT OF (INTER ALIA) INFLAMMATORY DISEASES, AUTOIMMUNE DISEASES OR VARIOUS KINDS OF CANCER | AMGEN INC. (US) | 2008-10-02 | — | — | WO | disclosed |
| WO-2008012635-A2 | AMINE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER PRODUCTS INC. (US) | 2008-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250360137-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | PDE9A, PDE3A, PDE2A | KDM4E 1355/4885ALDH1A1 1406/4885LMNA 1269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.